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Abstract 27 
Resveratrol offers pleiotropic health beneficial effects including its reported capability to 28 
inhibit lipopolysaccharide (LPS) induced cytokine production. The aim of this work was 29 
to prepare, characterize and evaluate a resveratrol nanoparticulate formulation based 30 
on zein. For this purpose the oral bioavailability of the encapsulated polyphenol as well 31 
as its anti-inflammatory effect in a mouse model of endotoxic shock were studied. 32 
Resveratrol-loaded nanoparticles displayed sizes around 300 nm with a negative zeta 33 
potential (- 51 mV) and a polyphenol loading close to 80 μg/mg. In vitro, the release of 34 
resveratrol from the nanoparticles was found to be pH-independent and adjusted well 35 
to the Peppas-Salin kinetic model, suggesting a mechanism based on the combination 36 
between diffusion and erosion of the nanoparticle matrix. Pharmacokinetic studies 37 
demonstrated that zein-based nanoparticles provided high and prolonged plasma 38 
levels of the polyphenol for at least 48 h. The oral bioavailability of resveratrol when 39 
administered in these nanoparticles increased up to 50% (20-fold higher than for the 40 
control solution of the polyphenol). Furthermore, nanoparticles administered daily for 7 41 
days at 15 mg/kg, were able to diminish the endotoxic symptoms induced in mouse by 42 
the ip administration of LPS (i.e. hypothermia, piloerection and stillness). In addition, 43 
serum TNF-α levels were slightly lower (about 15%) of those observed for the control.  44 
 45 
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Abbreviations 50 
Rsv: resveratrol  51 
SIRT1: sirtuin 1 52 
LPS: lipopolysaccharide from Salmonella enterica serovar. Minnesota 53 
Rsv-NP-Z: resveratrol-loaded zein nanoparticles  54 
NP-Z: empty zein nanoparticles 55 
Rsv-sol: resveratrol solution in a PEG 400: water mixture 56 
Rsv-susp: suspension of resveratrol in purified water  57 
PCS: photon correlation spectroscopy 58 
SEM: Scanning electron microscopy 59 
EE: encapsulation efficiency  60 
iv: intravenous 61 
Cmax: maximal serum concentration  62 
Tmax: time in which Cmax is reached  63 
AUC: area under the concentration-time curve from time 0 to last time  64 
MRT: mean residence time  65 
Cl: clearance  66 
V: volume of distribution  67 
t1/2: half-life in the terminal phase  68 
Fr: relative bioavailability  69 
FRD: fraction of resveratrol dissolved 70 
FRA: fraction of resveratrol absorbed 71 
ip: intraperitoneal 72 
PGE2: prostaglandin E2  73 
PDI: polydispersity index 74 
  75 
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Introduction 76 
Resveratrol (Rsv) (3,5,4’-trihydroxy-trans-stilbene), is a polyphenol molecule that was 77 
identified from the dried roots of Polygonum cuspidatum, a plant used in traditional 78 
Chinese and Japanese medicine 1. Resveratrol has been classified as a phytoalexin as 79 
it is synthesized in spermatophytes in response to injury, UV irradiation and fungal 80 
attack 2. It is naturally found in a wide variety of plant species, vegetables, fruits and 81 
food products  such as peanuts, grape skin, plums or red wine 2.  82 
Resveratrol offers pleiotropic health beneficial effects, including antioxidant and anti-83 
aging effects 3, cardioprotective 4, anticancer 1, neuroprotective 5 and HIV/AIDS 84 
activities 6. 85 
In the lasts years, it has been demonstrated the preventive effect of resveratrol against 86 
diabetes. Resveratrol would normalize hyperglycaemia and, in animals with 87 
hyperinsulinemia, it would reduce blood insulin 7. Similarly, resveratrol was reported to 88 
reduce body weight and adiposity in obese recipients 8. These actions would involve 89 
the activation of sirtuin 1 (SIRT1) that inhibits inflammatory pathways in macrophages 90 
and modulates insulin sensitivity 9. Furthermore, different studies have shown that 91 
resveratrol is capable of inhibiting lipopolysaccharide (LPS) induced cytokine 92 
production 10. This effect, via modulation of NF-κB, would decrease the production and 93 
gene expression of IL1 and TNF-α, important endogenous pyrogens 11. 94 
In spite of these potential health benefits, the use of resveratrol is limited due to its high 95 
lipohilicity, short biological half-life, and chemical instability. In addition, when 96 
resveratrol is orally administered, only trace amounts of the unchanged polyphenol can 97 
be detected in plasma 12. This low bioavailability is due to the polyphenol 98 
biotransformation by UDP-glucuronosyltransferase and sulphotransferases that 99 
produces resveratrol-3′-glucuronide and the sulphate derivative, respectively 2. In rats, 100 
the main metabolite of resveratrol is the glucuronide conjugate 13, whereas, in humans, 101 
both the glucuronide and the sulphate derivatives have been described 14. These 102 
metabolites have a longer plasma half-life, however, their efficacy are unknown 1. 103 
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Renal excretion is the major route of elimination of the polyphenol and its derivatives 104 
2,15.  105 
In order to solve these drawbacks different strategies have been pursued including its 106 
encapsulation in different oral delivery systems such as, among others, self-nano 107 
emulsifying drug delivery systems 16, solid lipid nanoparticles 17 and polymeric 108 
nanoparticles 18. 109 
An alternative approach might be the use of zein nanoparticles. Zein is the major 110 
storage protein of maize and comprises aprox. 45-50% of the total protein content in 111 
corn 19. Since zein is a natural protein, it is actually a heterogeneous mixture of 112 
different peptides than can be divided in four main fractions: i) α-zein (75-85% of total 113 
protein) with  two main MW of 21-25 kDa and 10kDa, ii) β-zein (10-15%) of a MW of 114 
17-18 kDa, iii) δ-zein, a minor fraction of 10kDa and vi) γ-zein (5-10%) with a MW of 27 115 
kDa 19,20. Zein is an amphiphilic protein, possessing high percentages of hydrophobic 116 
amino acids such as leucine (20%), proline (10%) and alanine (10%) 19,20. Due to this 117 
amino acid composition, zein is insoluble in water and, thus, the resulting devices (e.g. 118 
films, nanoparticles) display an hydrophobic character with interesting properties to 119 
control the release of the loaded compound 20,21. In addition, as for other nanocarriers 120 
from protein origin, they are biodegradable and can accommodate a great variety of 121 
compounds in a non-specific way 22. 122 
Therefore, the aim of this work was to prepare, characterize and evaluate a resveratrol 123 
nanoparticulate formulation based on zein and to study its oral bioavailability and anti-124 
inflammatory effect in a mouse model of induced endotoxic shock. 125 
 126 
Material and Methods 127 
Chemicals 128 
Zein, resveratrol, lysine, mannitol, sodium ascorbate, poly(ethylene glycol) 400 (PEG 129 
400) and Tween 20 were purchased from Sigma-Aldrich (Germany). Resveratrol-3-O-130 
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D-glucuronide (Rsv-O-glu) was from @rtMolecule (Poitiers, France). Ethanol, 131 
methanol, acetic acid and acetonitrile HLPC grade were obtained from Merck 132 
(Darmastadt, Germany). Lipopolysaccharide from Salmonella enterica serovar. 133 
Minnesota (LPS) was purchased from Sigma®, (St. Louis, USA). Deionised reagent 134 
water (18.2 MO resistivity) was prepared using a water purification system (Wasserlab, 135 
Spain). All reagents and chemicals used were of analytical grade.  136 
Preparation of resveratrol-loaded nanoparticles (Rsv-NP-Z) 137 
Nanoparticles were prepared by a desolvation method followed by an ultrafiltration 138 
purification step and subsequent drying in a spray-drier apparatus. Briefly, 600 mg zein 139 
and 100 mg lysine were dissolved in 60 mL of an ethanol:water mixture (65% ethanol 140 
by vol.). In parallel, 100 mg resveratrol were dissolved in 10 mL ethanol and 6 mL of 141 
this solution were transferred to the zein solution. In addition, 6 mg sodium ascorbate 142 
were added to minimise the oxidation of the polyphenol. The mixture was magnetically 143 
stirred in the dark for 10 min at room temperature. Nanoparticles were obtained by the 144 
continuous addition of 60 mL of purified water. The suspension was purified and 145 
concentrated by ultrafiltration using a 50 kDa pore size polysulfone membrane 146 
cartridge (Medica SPA, Italy). Then, 15 mL of purified water containing 1.2 g mannitol 147 
were added to the resulting suspension of nanoparticles to prevent aggregation and 148 
irreversible interactions among nanoparticles during the drying process. Finally the 149 
suspension was dried in a Büchi Mini Spray Drier B-290 apparatus (Büchi Labortechnik 150 
AG, Switzerland) under the following experimental conditions: (i) inlet temperature: 90 151 
°C, (ii) outlet temperature: 45-50 °C, (iii) air pressure: 4-6 bar, (iv) pumping rate: 5 152 
mL/min, (v) aspirator: 100% and (vi) air flow:  400-500 L/h. 153 
Control formulations (NP-Z) were prepared as described above but in absence of 154 
resveratrol. 155 
Preparation of resveratrol conventional formulations 156 
Two different formulations of resveratrol were also prepared. The first one, a solution of 157 
the polyphenol in a mixture of PEG400 and water (1:1 by vol.) was preparing dissolving 158 
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37.5 mg of resveratrol in 5 mL of PEG400 under magnetic stirring. Then 5 mL of 159 
purified water were added and the final mixture was agitated in the dark for 10 min. 160 
This formulation was named Rsv-sol. 161 
The second one was an extemporary suspension of resveratrol in purified water (Rsv-162 
susp). Briefly, 37.5 mg of resveratrol were dispersed in 10 mL of purified water under 163 
magnetic agitation for 10 min. The size of the resulting suspension was 21.4 ± 9.2 μm. 164 
The suspension was used after inspection for absence of aggregates. 165 
Characterization of nanoparticles 166 
Size, zeta potential and morphology 167 
The mean hydrodynamic diameter and the zeta potential of nanoparticles were 168 
determined by photon correlation spectroscopy (PCS) and electrophoretic laser 169 
Doppler anemometry, respectively, using a Zetamaster analyzer system (Malvern 170 
Instruments Ltd., Worcestershire, UK). The diameter of the nanoparticles was 171 
determined after dispersion in ultrapure water (1:10) and measured at 25 ºC with a 172 
scattering angle of 90 °C. The zeta potential was measured after dispersion of the dried 173 
nanoparticles in 1 mM KCl solution. 174 
The morphology of the nanoparticles was studied using a field emission scanning 175 
electron microscopy (SEM) in a Zeiss DSM940 digital scanning electron microscope 176 
(Oberkochen, Germany) coupled with a digital image system (Point Electronic GmBh, 177 
Germany). The yield of the process was calculated by gravimetry as described 178 
previously 22. 179 
Resveratrol analysis 180 
The amount of resveratrol loaded into the nanoparticles was quantified by HPLC-UV 181 
following an analytical method previously described 23 with minor modifications. 182 
Analysis were carried out in an Agilent model 1100 series LC coupled to a diode-array 183 
detector set at 306 nm. Data were analysed using Chemstation G2171 v. B.01.03 184 
software (Agilent, USA). The chromatographic system was equipped with a reverse 185 
C18 Alltima column (150 mm x 2.1 mm, particle size 5 μm; Altech, USA) and a Gemini 186 
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C18 support AJO-7596 precolumn. The mobile phase, pumped at 0.25 mL/min was a 187 
mixture of water/methanol/acetic acid in a gradient condition. The column was heated 188 
at 40 °C and the injection volume was 10 µL. Under these conditions, the retention time 189 
for resveratrol was 22.8±0.5 min. Calibration curves in ethanol 75% were designed 190 
over the range of 1-100 µg/mL (R2൒0.999). Under these experimental conditions, the 191 
limit of quantitation was calculated to be 200 ng/mL. 192 
For analysis, 10 mg nanoparticles were dispersed in 1 mL of water and centrifuged at 193 
30,500 g for 20 min. The amount of encapsulated resveratrol was calculated by 194 
dissolution of the pellets with 1 mL of ethanol 75%. Each sample was assayed in 195 
triplicate and the results were expressed as the amount of resveratrol (µg) per mg of 196 
nanoparticles. 197 
The encapsulation efficiency (E.E) was calculated as follows: 198 
ܧ. ܧ. ሺ%ሻ ൌ ோ௦௩	௣ோ௦௩೟ ൈ 100   [Eq. 1] 199 
where Rsv-t is the total  amount of resveratrol in the formulations and, Rsv-p, the 200 
amount of resveratrol quantified in the pellet. 201 
In vitro release study 202 
Release experiments were conducted under sink conditions at 37°C using simulated 203 
gastric (pH 1.2; SGF) and intestinal (pH 6.8; SIF) fluids 22, containing 0.5% Tween 20 204 
as surfactant to increase the resveratrol aqueous solubility. The studies were 205 
performed under agitation in a slide-A-Lyzer® Dialysis cassete 10000 MWCO (Thermo 206 
scientific, Rockford, IL, USA). For this purpose, the cassette was filled with 3 mg of 207 
resveratrol nanoparticles previously dispersed in 5 mL water and, then, introduced in a 208 
vessel containing 500 mL of SGF (pH 1.2; 37ºC) under magnetic stirring. After 2 h in 209 
SGF, the cassette was introduced in another vessel containing 500 mL of thermostat-210 
zed SIF (pH 6.8; 37ºC, under agitation). At different time points, samples were 211 
collected and filtered through 0.45 µm size-pore filters (Thermo scientific, Rockford, 212 
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USA) before quantification by HPLC. Calibration curves of resveratrol in SGF and SIF 213 
(0.05-6 µg/mL; R2 ≥ 0.999 in both cases) were performed.  214 
In order to ascertain the resveratrol release mechanism the obtained data were fitted to 215 
the Korsmeyer-Peppas and the Peppas-Sahlin models. The Korsmeyer–Peppas model 216 
is a simple semi-empirical approach which exponentially relates drug release with the 217 
elapsed time as expressed in the following equation 24: 218 
n·tK KP
t
M
M 

   [Eq. 2] 219 
where Mt /M∞ is the drug release fraction at time t, KKP is a constant incorporating the 220 
structural and geometric characteristics of the matrix and n is the release exponent 221 
indicative of the drug release mechanism 25. Values close to 0.5 indicate a Case I 222 
(Fickian) diffusion mechanism and values between 0.5 and 0.89 indicate anomalous 223 
(non-Fickian) diffusion. Values of n between 0.89 and 1 indicate Case II transport, 224 
erosion of the matrix. 225 
The contribution of Fickian and non-Fickian release was also evaluated by using the 226 
Peppas–Sahling model equation 26: 227 
·tK·tK E
1/2
D 
M
Mt   [Eq. 3] 228 
where the first term of the right-hand side is the Fickian contribution (KD is the 229 
diffusional constant) and the second term is the Case II erosional contribution (KE is the 230 
erosional constant). KD and KE values were used to calculate the contribution 231 
percentage of diffusion (D) and erosion (E) as follows 26: 232 
ܦ ൌ ଵଵା಼ಶ಼ವ௧బ.ఱ
  [Eq 4] 233 
ா
஽ ൌ
௄ಶ
௄ವ ݐ
଴.ହ  [Eq 5] 234 
Only one portion of the release profile (Mt/M∞ ≤ 0.6) was used to fit the experimental 235 
data to the previous equation.  236 
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In vivo pharmacokinetic studies in Wistar rats 237 
Pharmacokinetic studies 238 
Pharmacokinetic studies were performed in male Wistar rats (200-250 g) obtained from 239 
Harlan (Barcelona, Spain). Studies were approved by the Ethical Committee for Animal 240 
Experimentation of the University of Navarra (protocol number 028-11) in accordance 241 
with the European legislation on animal experiments. 242 
Prior to the oral administration of the formulations, animals were fasted overnight to 243 
avoid interference with the absorption, allowing free access to water. For the 244 
pharmacokinetic study, rats were randomly divided into 4 groups of 6 animals each. 245 
The three experimental groups were: (i) resveratrol water suspension (Rsv-susp), (ii) 246 
resveratrol solution in a PEG400:water mixture (Rsv-sol) and (iii) resveratrol-loaded 247 
zein nanoparticles (Rsv-NP-Z). As control, a group of animals was treated 248 
intravenously with the PEG400:water (1:1 by vol.) solution of resveratrol. Each animal 249 
received the equivalent amount of resveratrol to a dose of 15 mg/kg body weight either 250 
by oral gavage or intravenously via tail vein. 251 
Blood samples were collected at set times after administration (0, 10 min, 30 min, 1 h, 252 
2 h, 4 h, 6 h, 8 h, 24 h and 48 h) in specific plasma tubes (Microvette® 500K3E, 253 
SARSTEDT, Germany).  Samples were immediately centrifuged at 9,400 g for 10 min 254 
and plasma aliquots were kept frozen at -80 ºC until HPLC analysis of both resveratrol 255 
and resveratrol-3-O-D-glucuronide. 256 
Determination of resveratrol and resveratrol-3-O-D-glucuronide plasma 257 
concentration by HPLC 258 
The amount of resveratrol was determined by HPLC-UV following an analytical method 259 
previously reported with minor modifications 27. Analysis were carried out in an Agilent 260 
model 1100 series LC and diode-array detector set at 306 nm. Data were analysed in a 261 
Chemstation G2171 program (B.01.03). The chromatographic system was equipped 262 
with a reversed-phase C18 Kromasil column (250 mm x 2.1 mm; particle size 5 µm) 263 
and a Gemini C18 support AJO-7596 precolumn. The mobile phase, pumped at 0.5 264 
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mL/min, was a mixture of water, methanol and acetic acid (50:45:5 by vol.) under 265 
isocratic conditions. The column was thermostatized at 30°C and the injection volume 266 
was 30 µL. Under these conditions, the retention times for resveratrol-3-O-D-267 
glucuronide and resveratrol were 6.2 ± 0.5 min and 12.6 ± 0.5 min, respectively.  268 
For analysis, a 100 µL aliquot of plasma was mixed with 50 µL HCl 0.1 N and 500 µL 269 
acetonitrile (for protein precipitation) followed by vigorous shaking. Then, samples were 270 
centrifuged at 4000 rpm for 10 min and the obtained supernatants were evaporated 271 
under vacuum in a Speed Vac® system (Holbrook, NY) at 25°C for 30 min. Finally, 100 272 
µL of a mixture of acetonitrile and water (1:1 by vol.) was added and vigorously stirred 273 
in a vortex for 10 min. Then, and prior to the injection, samples were filtered through 274 
0.45 µm filter (Thermo scientific, Rockford, IL, USA). 275 
For quantification, calibration curves were prepared over the range 2 to 70 µg/mL for 276 
the metabolite and 50 to 3,000 ng/mL for resveratrol (R2൒0.99). All the calibration 277 
standards were obtained by adding either resveratrol or resveratrol-3-O-D-glucuronide 278 
in acetonitrile (500 µL) to 100 µL plasma from non-treated animals. Then, the 279 
polyphenol or its metabolite was extracted using the same protocol described above. 280 
Under these experimental conditions, the limit of quantification was calculated to be 70 281 
ng/mL, for resveratrol, and 4 µg/mL for the metabolite. Linearity, accuracy and 282 
precision values during the same day (intra-day assay) at low, medium and high 283 
concentrations of both resveratrol and the metabolite were always within the 284 
acceptable limits (relative error and coefficient of variation less than 15%). 285 
Pharmacokinetic data analysis 286 
Resveratrol plasma concentration was plotted against time, and pharmacokinetic 287 
analysis was performed using a non-compartmental model with the WinNonlin 5.2 288 
software (Pharsight Corporation, USA). The following parameters were estimated: 289 
maximal serum concentration (Cmax), time in which Cmax is reached (Tmax), area under 290 
the concentration-time curve from time 0 to the last sampling-point (48 h)  (AUC), mean 291 
residence time (MRT), clearance (Cl), volume of distribution (V) and half-life in the 292 
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terminal phase (t1/2). Furthermore, the relative bioavailability (Fr %) of resveratrol was 293 
estimated by the following equation: 294 
ܨݎ	ሺ%ሻ ൌ ஺௎஼	௢௥௔௟஺௎஼	௜௩ 	ൈ 100     (Eq. 6) 295 
where AUCi.v. and AUCoral are the areas under the curve for the iv and oral 296 
administrations, respectively. 297 
In vitro/In vivo correlation (INVIC) 298 
The eventual correlation between in vitro and in vivo results was conducted by plotting 299 
a point-to-point between the amount of resveratrol released from nanoparticles vs the 300 
fraction of resveratrol absorbed (FRA) calculated from the mean plasma concentration-301 
time inputs using the Wagner-Nelson equation 28: 302 
ܨܴܣ ൌ ஼೟ା௞ൈ஺௎஼బష೟௞	ൈ஺௎஼	బషಮ      (Eq. 7) 303 
where Ct is the plasma concentration of resveratrol at a time t, k is the elimination rate 304 
constant of the polyphenol, AUC 0-t is the area under the resveratrol concentration vs. 305 
time curve from 0 to time t, and AUC 0-∞ is the area under the curve from 0 to infinity.  306 
Linear regression analysis was applied to the in vitro–in vivo correlation plot and 307 
coefficient of determination (R2) was calculated. 308 
Anti-inflammatory efficacy study 309 
Animal model 310 
Four weeks-old (20-22 g) C57BL/6J female mice were purchased from Harlan 311 
(Barcelona, Spain) and housed in standard animal facilities (6 animals per cage with 312 
free access to food and drinking water). Housing conditions were maintained by 313 
controlled temperature and humidity and with 12 h on/off light cycles. Animals were 314 
allowed to acclimate for one week before the experiment. 315 
In vivo anti-inflammatory studies were evaluated in an endotoxic shock model set up by 316 
intraperitoneal (ip) administration of LPS at a dose of 40 µg per mouse 29. Before 317 
administration, LPS was dissolved in PBS and vortexed during 30 min to complete 318 
homogenization.  319 
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On day 1, mice were randomly distributed into four groups. The first group of animals 320 
received an oral dose of 15 mg/kg resveratrol daily as oral solution (Rsv-sol) during 7 321 
days. The second group of animals received the same posology of polyphenol (15 322 
mg/kg resveratrol daily; 7 days) but formulated in zein nanoparticles (Rsv-NP-Z).. As 323 
controls, a group of animals received LPS treatment (positive control group) and 324 
another one received neither LPS nor resveratrol (negative control group).   325 
Twenty-four hours after the last dose of resveratrol (day 8) animals were challenged 326 
with 40 μg LPS by ip route. Throughout the study, rectal temperature of mice was 327 
measured until 24 h after challenge. Similarly, animals were observed for any clinical 328 
signs or symptoms of toxicity daily and after the challenge. The severity of symptoms 329 
was scored as follows:: i) (-) absent; ii) (+) weak; iii) (++) moderate; and iv) (+++) 330 
strong. Depending on the activity of animals, their mobility was classified as very low, 331 
low or normal. 332 
In addition, 90 min after challenge, blood samples were collected from the retro-orbital 333 
cavity in EDTA-K vials (Microvette® 500K3E, SARSTEDT, Germany), centrifuged at 334 
8,000 g for 10 min for sera collection and stored at -20 °C until use. 335 
Measurement of plasma TNF-α 336 
The concentration of circulating TNF-α in the serum was determined by an enzyme-337 
linked immunosorbent assay kit (Quantikine® ELISA Mouse TNF-α, MTA00B, R&D 338 
Systems, Minneapolis, USA) according to manufacturer’s instructions. 339 
Statistical analysis 340 
Data are expressed as the mean ± standard deviation (S.D.) of at least three 341 
experiments. The non-parametric Kruskall-Wallis followed by Mann-Whitney U-test was 342 
used to investigate statistical differences. In all cases, p< 0.05 was considered to be 343 
statistically significant. All data processing was performed using Graph Pad® Prism 344 
statistical software.  345 
 346 
Results 347 
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Preparation and characterization of nanoparticles 348 
Table 1 shows the physico-chemical characteristics of the nanoparticles used in this 349 
study. Overall, the mean diameter of empty nanoparticles was smaller than those 350 
loaded with resveratrol. When resveratrol was encapsulated, zein nanoparticles 351 
displayed a mean size of about 310 nm, whereas, the polydispersity index was found to 352 
be lower than 0.2, indicating homogeneous nanoparticle formulations. Furthermore, the 353 
zeta potential of nanoparticles was negative (- 51 mV); however, when resveratrol was 354 
encapsulated the resulting nanoparticles were slightly more negative than for empty 355 
ones (Table 1). Additionally, the resveratrol loading was calculated to be about 80 356 
μg/mg nanoparticles, with an encapsulation efficiency close to 82%. 357 
Figure 1 shows the morphology and shape of resveratrol-loaded nanoparticles.  In all 358 
cases, nanoparticles consisted of homogeneous populations of spherical particles with 359 
a smooth surface. In addition, the size of nanoparticles as observed by SEM was in line 360 
with the values determined by photon correlation spectroscopy (Table 1).  361 
In vitro release profile 362 
Figure 2A represents the release profile of resveratrol from nanoparticles expressed 363 
as cumulative percentage of drug released versus time. In all cases, the release of 364 
resveratrol from zein-based nanoparticles was found to be independent of the pH 365 
conditions. During the first 2 h, under SGF conditions (pH 1.2), about 20% of the 366 
loaded resveratrol was released from zein nanoparticles. Then, 6 hours later (during 367 
incubation in SIF conditions) the amount released was close to 60% of the total content 368 
of resveratrol. After 48 h, all the loaded resveratrol was released from nanoparticles.  369 
The release profile of resveratrol from NPs was fitted to different mathematical release 370 
models. Using the Korsmeyer-Peppas equation, R2 values were high (R2>0.96) and the 371 
exponent “n” value was 0.75±0.06. All of this suggests that the release of resveratrol 372 
from nanoparticles would be a combination of Fickian diffusion and erosion of the 373 
nanoparticle matrix. Under these circumstances, the Peppas-Sahlin model was applied 374 
and the erosion (KE) and diffusion (KD) constants were calculated (KD = 0.08±0.02 h-1/2; 375 
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KE: 0.04±0.01 h-1). Figure 2B displays the contribution of both the diffusion and erosion 376 
mechanisms on the release of resveratrol from zein nanoparticles. The time at which 377 
both mechanisms (diffusion and erosion) contributed in a similar amount to the release 378 
of resveratrol was calculated to be 3.5 h.  379 
In vivo pharmacokinetics 380 
Figure 3A shows the plasma concentration-time profile of a resveratrol solution in 381 
PEG-400:water (1:1 by vol.) after the intravenous administration to rats of a single dose 382 
of 15 mg/kg. The data were adjusted to a non-compartmental model. The resveratrol 383 
plasma concentration decreased rapidly in a biphasic way during the first 8-h post 384 
administration. The peak plasma concentration (Cmax) of resveratrol was around 15 385 
µg/mL, whereas the AUC and half-life (t1/2) were calculated to be 11.4 µg h/mL and 2.0 386 
h, respectively. The resveratrol clearance and its volume of distribution were about 0.2 387 
L/h and 0.6 L, respectively (Table 2). 388 
Figure 3B shows the plasma concentration levels of resveratrol when administered 389 
orally as a single dose of 15 mg/kg to rats. Interestingly, when resveratrol was 390 
formulated as a suspension, no detectable levels of the polyphenol were quantified in 391 
plasma. On the other hand, when resveratrol was administered as solution (Rsv-sol), 392 
the polyphenol plasma levels displayed an initial maximum concentration (Cmax) of 393 
around 0.2 µg/mL, 30 min after administration. Then, the plasma levels of resveratrol 394 
decreased rapidly and quantifiable levels were only detected during the first 4 h post-395 
administration. 396 
For resveratrol-loaded in zein nanoparticles (Rsv-NP-Z), the amount of the polyphenol 397 
in plasma increased during the first 4 h after administration until reaching a maximum. 398 
Then, the resveratrol plasma levels decreased slowly for the following 20 h. Forty-eight 399 
hours post-administration, the amount of resveratrol in plasma was very close to the 400 
quantitation limit of the analytical technique.  401 
Table 2 summarizes the main pharmacokinetic parameters estimated with a non-402 
compartmental analysis of the experimental data obtained after the administration of 403 
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the different formulations to rats. The resveratrol AUC values from zein nanoparticle 404 
formulations were significantly higher (p< 0.05) than those observed for the polyphenol 405 
solution. Similarly, the resveratrol MRT was thirteen-times higher when administered in 406 
the form of zein nanoparticles than when solubilized in the PEG400:water oral mixture. 407 
Finally, the relative oral bioavailability of resveratrol when incorporated in nanoparticles 408 
was calculated to be 50 % using zein nanoparticles. This value was significantly higher 409 
than the bioavailability obtained with the PEG400:water solution (2.6 %). 410 
Figure 4 shows the plasma concentration versus time profile of the resveratrol main 411 
metabolite (resveratrol-O-3-glucuronide) after the single administration of the 412 
polyphenol in the formulations tested. Interestingly, the profile of the plasma curves for 413 
both resveratrol and its metabolite were similar; however, the metabolite levels were 414 
always higher than for the polyphenol. When resveratrol was administered 415 
intravenously, the metabolite concentration reached 41.9 µg/mL (Cmax) and, then, the 416 
metabolite levels decreased sharply. The AUC value was calculated to be 197 µg 417 
h/mL. 418 
For the solution of resveratrol orally administered, the Cmax of the metabolite in plasma 419 
was found to be 2-times lower (22.1 µg/mL) than when administered by the iv route. In 420 
this case, the metabolite was only quantified in plasma during the first 8 h post-421 
administration. The AUC value was calculated to be 104 µg h/mL; around half the i.v. 422 
solution one. 423 
For nanoparticles, the metabolite was quantified during the first 24 hours after 424 
administration. In addition, the metabolite AUC data was around 342 µg h/mL for Rsv-425 
NP-Z. This value was around three-times higher than with the resveratrol was 426 
administered as oral solution or intravenously. 427 
In vitro-in vivo correlations 428 
Figure 5 represents the relationship between the in vitro dissolution data (expressed 429 
as the cumulative percentage of the polyphenol released) and the fraction of 430 
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resveratrol absorbed during the first 8 h post-administration. An acceptable linear 431 
regression was observed between both data (R2 = 0.83 for Rsv-NP-Z).  432 
Anti-inflammatory efficacy study 433 
Figure 6A shows rectal temperature of mice for 24 h after ip administration of 40 µg 434 
LPS Before challenge, all the animals displayed a similar rectal temperature (data not 435 
shown). However, six hours after challenge, important differences were observed 436 
among groups. Thus positive control animals (without any resveratrol treatment) 437 
displayed a body temperature of about 4ºC below the basal normal levels. For animals 438 
treated with Rsv-sol the body temperature was 3ºC lower than before challenge. On 439 
the contrary, rectal temperature of animals treated with resveratrol loaded in zein 440 
nanoparticles, decreased only 0.5-1 °C. No variations were observed in the control 441 
negative group. Twenty-four hours after challenge animals treated with free resveratrol 442 
or encapsulated regained normal temperature. 443 
Table 3 shows the overall endotoxic symptoms score including the number of animals 444 
displaying a temperature 2 ºC lower than the basal temperature, 6 h post-challenge. 445 
Positive control animals displayed a low mobility and signs of bristly hair and 446 
respiratory distress. On the contrary, animals treated with Rsv-NP-Z displayed an 447 
almost normal behaviour and an evident better symptomatology than those animals 448 
receiving resveratrol as oral solution, which appeared to be immobile or with a high 449 
difficulty to coordinate any simple movement. 450 
Figure 6B shows the serum levels of TNF-α measured by ELISA before and 90 min 451 
after LPS challenge. Negligible levels of TNF-α were observed before LPS 452 
administration. The oral administration of Rsv-NP-Z induced a decrease in the levels of 453 
TNF-α with respect to mice pre-treated with resveratrol solution and the positive control 454 
group; however, these differences were not statistically significant. Significant 455 
differences (p<0.01) were observed between control negative and the rest of groups. 456 
 457 
Discussion 458 
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In the past zein was proposed as material for the preparation of nanoparticles due to its 459 
hydrophobic character, degradability, adherence properties and versatile processability 460 
19,20. However, as zein possesses abundant non-polar amino acids, the dispersability of 461 
the resulting nanoparticles in an aqueous media (and, therefore, their potential 462 
applications) is a challenge 30. Recently, the use of citrate and phosphate salts was 463 
proposed to minimize this problem 31. In our case, lysine was added during the 464 
preparative process of nanoparticles. In this way, the resulting dry powder of zein 465 
nanoparticles was easily redispersed, yielding a homogeneous fine suspension (Table 466 
1) after the addition of water and simple hand agitation.  467 
Resveratrol-loaded zein nanoparticles (Rsv-NP-Z) displayed a mean size close to 300 468 
nm and negative zeta potential. The resveratrol loading was of 80 µg/mg nanoparticles 469 
with an encapsulation efficiency of 80%. This payload is in line with values previously 470 
reported by using solid lipid nanoparticles 17, PLGA nanoparticles 18, or nanoemulsions 471 
32. The release of resveratrol from zein nanoparticles was found to be pH-independent. 472 
In fact, this phenomenon would be a combination of both Fickian diffusion and erosion 473 
of the nanoparticle matrix (Peppas-Sahlin model). During the first hours of the release 474 
process, resveratrol molecules would mainly diffuse from the nanoparticles to the 475 
aqueous medium by Fickian diffusion. Later (3.5 h), the release of resveratrol would be 476 
mainly due to an erosion and/or relaxation process of the nanoparticle matrix. 477 
Interestingly, as a consequence of both phenomena, the amount of resveratrol 478 
released (at least during the first 8 h) is constant and approaches to a zero order 479 
kinetic.  480 
Pharmacokinetic studies were carried out at a single dose of 15 mg/kg, comparable to 481 
those used in previous studies 33,34. The oral administration of a single dose of 482 
resveratrol as an aqueous suspension (Rsv-susp) to rats did not produce quantifiable 483 
levels of the polyphenol in plasma (Figure 3B). For the solution formulation, in a 484 
PEG400:water mixture (Rsv-sol), the plasma levels of the polyphenol were higher than 485 
for the suspension but they rapidly decreased and 6 h-post administration only traces 486 
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of resveratrol in plasma were detected. These findings are directly related with the 487 
extensive metabolism of resveratrol 35. In fact, when administered orally, resveratrol 488 
(due to its lipophilic character) can rapidly enter into the enterocyte by passive diffusion 489 
36; although, it is highly metabolized to glucuronide and sulphate derivatives, which may 490 
be secreted back to the intestinal lumen through multidrug resistance protein 2 (MRP2) 491 
and BCRP 37,38. This extensive biotransformation of resveratrol decreases circulation 492 
levels of free resveratrol and facilitates its excretion (in the form of conjugates) by the 493 
kidneys via urine 14. Controversy remains about the physiological activity of metabolites 494 
or if they can act as resveratrol prodrugs. There are evidences that, at sufficient 495 
concentrations, resveratrol metabolites have biological activity in various tissues 36. 496 
Nevertheless, there are also evidences that these compounds have no effects in some 497 
tissues 39. 498 
However, when resveratrol was administered after its encapsulation in zein 499 
nanoparticles, sustained and prolonged plasma levels of the polyphenol were observed 500 
for at least 24 h (Figure 3B) and its relative oral bioavailability was about 50% (Table 501 
3), which is about 18-fold higher than the value observed for Rsv-sol (about 2.6%). This 502 
increased capability to promote the absorption and bioavailability of resveratrol by 503 
using zein nanoparticles would be related with its high hydrophobic character, that 504 
would offer a higher stability in vivo, and to the capability of this corn protein to develop 505 
mucoadhesive interactions within the gut mucus layer 40. Thus, this characteristic would 506 
provide a longer residence in close contact with the intestinal epithelium and facilitating 507 
the establishment of a concentration gradient from the nanoparticulate matrix untill the 508 
absorptive membrane. Interestingly, the fraction of resveratrol absorbed from zein 509 
nanoparticles correlated well with the percentage of the polyphenol released in vitro 510 
(see Figure 5). 511 
In previous studies, it has been reported that the oral bioavailability of resveratrol is 512 
almost zero 34,41. In order to improve its absorption different strategies have been 513 
proposed such as the use of oral absorption enhancers (e.g. Tween 80, cyclodextrins) 514 
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or the employment of resveratrol derivatives. In this way, Kapetanovic and co-workers 515 
have reported an oral bioavailability of resveratrol (formulated as aqueous solution 516 
containing methylcellulose and Tween 80) close to 30% after the administration of a 517 
single dose of 50 mg/kg in rats. In the same work, the administration of the same 518 
resveratrol formulation at a dose of 150 mg/kg produced an oral bioavailability of 19% 519 
42. In another work, resveratrol trimethyl-ether administered orally in a solution 520 
formulated with randomly methylated-β-cyclodextrin (15 mg/kg) yielded a bioavailability 521 
of about 47%. More recently, the use of nanocarriers has also been proposed. Thus, in 522 
mice and using a dose of 50 mg/kg, the oral bioavailability of resveratrol when loaded 523 
in either Eudragit or chitosan/lecithin nanoparticles was calculated to be 39 and 61%, 524 
respectively 43. For solid lipid nanoparticles, the oral bioavailability of the polyphenol 525 
was found to be 8-fold higher than for a conventional solution of resveratrol 44. In our 526 
case, the resveratrol bioavailability was 18-fold higher when loaded in zein 527 
nanoparticles than when dissolved in the PEG400:water solution. Furthermore, zein 528 
nanoparticles offering sustained and prolonged levels of resveratrol in plasma provided 529 
a supplementary advantage when compared with other strategies. 530 
Regarding the presence of the main metabolite (resveratrol-O-3-glucuronide 13) in the 531 
plasma of animals, the levels of this compound (measured as AUC) were higher when 532 
resveratrol was administered encapsulated in zein nanoparticles than when 533 
administered in the conventional solution both by iv route (about 1.7 times) or orally 534 
(around 3.3 times). This fact would be related with the slow release of the polyphenol 535 
from the nanoparticles (where protected from degradation) and a prolonged residence 536 
of nanoparticles in the gut mucosa due to their mucoadhesive properties. In other 537 
words, by using nanoparticles, more resveratrol and during a longer period would reach 538 
the circulation, counterbalancing the natural rapid metabolism of the drug.  539 
Finally, we studied the anti-inflammatory activity of resveratrol when loaded in zein 540 
nanoparticles. Several in vitro and in vivo studies suggest that resveratrol inhibits the 541 
inflammatory response mediated by microbial stimuli 45; by inhibiting the transcription 542 
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factor NF-κB 10,11. Therefore, we tested here the protective effect of encapsulated 543 
resveratrol against the inoculation of LPS in mice. LPS is present exclusively on the 544 
outer membrane of Gram negative bacteria, and consequently, it is one of the most 545 
strong alarm signals for the innate immune system, inducing in animals a 546 
pathophysiologic syndrome known as endotoxic shock. This syndrome is similar to 547 
sepsis shock syndrome that progress on multiple organ failure 29,46, showing 548 
piloerection, hypothermia, shivering, tachycardia and lethargy. These symptoms are 549 
related with large amounts of released inflammatory mediators, such as TNF-α, NO 550 
and prostaglandin E2 (PGE2), where TNF-α play a central role as being the first one to 551 
be released 10. In our experimental conditions, untreated mice challenged with LPS 552 
(positive control) displayed the highest decrease in rectal temperature and the highest 553 
TNF-α serum level. In contrast, Rsv-NP-Z administered daily during 7 days, were able 554 
to diminish endotoxic symptoms like hypothermia or piloerection and increase the 555 
movement of mice compared to those treated with resveratrol solution on daily basics 556 
(Figure 6, Table 3). Moreover, for animals treated with Rsv-NP-Z, TNF-α levels were 557 
lower than for controls; although the high variability of values abolished the statistical 558 
significance. These results appear to indicate that the presence of sustained high 559 
levels of resveratrol in plasma could be efficient to reduce the inflammatory mediators 560 
in endotoxic shock induced by LPS. 561 
In summary, zein nanoparticles appear to be interesting carriers for the oral delivery of 562 
resveratrol. The polyphenol is released from this carrier by a combination of both 563 
diffusion and erosion of the nanoparticle matrix, providing higher and more prolonged 564 
plasma levels of resveratrol up to 48 h. Consequently, these nanocarriers significantly 565 
increased the oral bioavailability of resveratrol reaching a value close to 50%. The oral 566 
administration of these nanoparticles during one week to mice challenged with LPS 567 
protected them from the inflammatory symptoms and mediators of the endotoxic shock. 568 
Future studies should be performed to ascertain how this treatment modulates TNF-α 569 
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production in order to explore the potential use of Rsv-NP-Z as anti-inflammatory 570 
treatment. 571 
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Figure captions  705 
Figure 1. Scanning electron microscopy (SEM) microphotograph of resveratrol-loaded 706 
zein nanoparticles. Bar indicates the resolution (1 µm). The white box delimits a 707 
magnified area. 708 
Figure 2. Resveratrol release from zein-based nanoparticles (Rsv-NP-Z). A) 709 
Resveratrol release profile when incubated in simulated gastric (SGF, pH 1.2; 0-2 h) 710 
and simulated intestinal fluids (SIF, pH 6.8; 2-48 h) under sink conditions. Data 711 
represented as mean ± SD (n=3).  B) Fraction contribution of the Fickian diffusion (●) 712 
and the erosion/relaxation (○) mechanisms to resveratrol release from zein 713 
nanoparticles (Rsv-NP-Z). 714 
Figure 3. Resveratrol plasma concentration vs time after a single administration of the 715 
polyphenol at a dose of 15 mg/kg.  A)  Intravenous administration of the resveratrol 716 
solution in the PEG400:water mixture. B) Oral administration of the following 717 
resveratrol formulations: i) resveratrol suspension (Rsv-susp, ▲), ii) resveratrol solution 718 
(Rsv-Sol, ♦) and iii) resveratrol-loaded zein nanoparticles (Rsv-NP-Z, ■). Data 719 
expressed as mean ± SD (n=6). 720 
Figure 4. Resveratrol-O-3-glucuronide concentration vs time after a single 721 
administration (intravenous or oral) of the different formulations at dose of 15 mg/kg. i) 722 
Resveratrol intravenous (Rsv-IV, ◊) ii) Oral resveratrol solution (Rsv-Sol, ▲), and iii) 723 
Oral resveratrol loaded in zein nanoparticles (Rsv-NP-Z, ■). Data expressed as mean ± 724 
SD, n= 6. 725 
Figure 5. Relationship between fractions dissolved in vitro vs. fraction absorbed in vivo 726 
of Resveratrol loaded into zein nanoparticles (Rsv-NP-Z). FRD (fraction of resveratrol 727 
dissolved), FRA (fraction of resveratrol absorbed). 728 
 28 
 
Figure 6: Anti-inflammatory activity of resveratrol. A) Comparative of decreased rectal 729 
temperature of mouse after ip administration of LPS (40 µg) on time. B) TNF-α serum 730 
levels before and 1.5 h post LPS (40 µg) administration. Mice were pre-treated orally 731 
daily for 7 days with resveratrol loaded in zein nanoparticles (Rsv-NP-Z) or resveratrol 732 
solubilized in PEG400-H2O (Rsv-sol) (1:1 by vol.).  No pre-treated with resveratrol 733 
(control +) and negative controls (no pretreated with resveratrol and no treated with 734 
LPS) were also included. Results expressed as mean ± SD (n=6).***p<0.01 Kruskal 735 
Wallis test. 736 
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Tables 
Table 1. Physico-chemical characteristics of empty and resveratrol-loaded 
nanoparticles. NP-Z: empty zein nanoparticles; Rsv-NP-Z: resveratrol-loaded 
zein nanoparticles. PDI: polydispersity index. Data expressed as mean ± SD, 
n=6. 
 
 
 
a Determination of volume mean diameter by photon correlation spectroscopy 
b Determination of resveratrol content by HPLC-UV 
c Encapsulation efficiency (%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Size 
(nm)a 
PDI 
 
Zeta potential 
(mV) 
 
Rsv loading 
(µg/mg NP)b 
 
E.E. 
(%)c 
NP-Z 264 ± 2 0.07 ± 0.01 -46 ± 2   
Rsv-NP-Z 307 ± 3 0.10 ± 0.01 -51 ± 0 80 ± 3 82 ± 4 
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Table 2. Pharmacokinetic parameters of resveratrol obtained after the administration of the different formulations tested at a dose of 
15 mg/kg to Wistar male rats. i) Resveratrol intravenous (Rsv-iv) ii) Rsv solution (Rsv-sol), iii) Resveratrol suspension (Rsv-susp) 
and iv) Resveratrol loaded in zein nanoparticles (Rsv-NP-Z). Data expressed as mean ± SD. (n=6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cmax: peak plasma concentration; Tmax: time to reach plasma concentration; AUC: Area under the curve; t ½: half life 
of the terminal phase; Cl: Clearance; MRT: mean residence time Fr: relative oral bioavailability 
† Significant differences vs Rsv-Sol (p<0.05) Mann-Whitney-U 
* Significant differences vs Rsv-i.v. (p<0.01) Mann-Whitney-U 
 
 
 
 Route 
C max 
(µg/mL) 
T max 
(h) 
AUC 
(µg h/mL) 
T ½        
(h) 
Cl 
(mL/h) 
Vd 
(mL) 
MRT 
(h) 
Fr 
(%) 
Rsv iv. iv 15.2± 5.18 0.1±0.0 10.4 ± 3.80 2.0±0.5 199 ± 89.8 569 ± 221 2.4±1.0 100 
Rsv-sol oral 0.20 ± 0.02* 0.6±0.2 0.28 ± 0.13* 0.3±0.2 387 ± 225 112 ±104 1.3±0.8 2.6 
Rsv-susp oral ND ND ND ND ND ND ND ND 
Rsv-NP-Z oral 0.39 ± 0.11*† 4.9 ± 3.1 5.17 ± 2.61† 5.5 ± 1.7 125 ± 41 909 ± 184 17.1 ± 7.1*† 50.0 
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Table 3. Endotoxic symptoms in the resveratrol treated vs no treated LPS-
inoculated mice.  
 
 
 
 
 
 
 
 
 
 
*Control -: No treated, no LPS; Control +: No treated but inoculated with LPS; Rsv-Sol: 
administration of resveratrol solution daily during 7 days, LPS; Rsv-NP-Z: 
administration of resveratrol-loaded zein nanoparticles daily during 7 days, LPS. 
(n=6).Severity of the symptoms: (-) None; (+) weak; (++) moderate; (+++) strong.  
**, Decreased of temperature 6 h after LPS inoculation. 
   
Treatment* Tª decreased** >2°C Piloerection Mobility 
Control - 0/6 - Normal 
Control + 6/6 +++ Very low 
Rsv-Sol 4/6 ++ Very Low 
Rsv-NP-Z 1/6 + Low 
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